KR-20260067144-A - Tablet comprising extract of potentilla chinensis and method of producing the same

Abstract

The present invention relates to a tablet containing a Weilingcai extract and a method for manufacturing the same.

Inventors

• 임순호
• 곽유진

Assignees

• 동신대학교산학협력단

Dates

Publication Date

20260512

Application Date

20241105

Claims (20)

1. A tablet comprising Potentilla chinensis extract as an active ingredient, and comprising excipients and binders as pharmaceutically acceptable additives.
2. In Article 1, A tablet comprising one or more additives selected from the group consisting of disintegrants and lubricants.
3. In Article 1, The above excipient is a mixture of lactose and microcrystalline cellulose mixed in a weight ratio of 1:1, and is contained in an amount of 59 to 72 weight% based on the total weight of the tablet.
4. In Article 1, A tablet in which the binder is hydroxypropyl cellulose (HPC) and is contained in an amount of 3 to 10 weight percent based on the total weight of the tablet.
5. In Paragraph 2, A tablet in which the disintegrant is crospovidone and is contained in an amount of 2 to 10 weight percent based on the total weight of the tablet.
6. In Paragraph 2, The above lubricant is sodium stearyl fumarate, and the tablet is contained in an amount of 1% by weight based on the total weight of the tablet.
7. In Article 1, The above Weilingcai extract is a purified product obtained by reflux extracting the whole Weilingcai plant using 40% ethanol, concentrating, drying, and grinding the extract into a powder.
8. In Article 1, The above Weilingcai extract is a tablet containing one or more of ellagic acid, isoquercitrin, and miquelianin.
9. In Article 1, A tablet having a disintegration time of 30 minutes or less when tested in purified water according to the disintegration test method of the Korean Pharmacopoeia.
10. In Article 1, The above tablet is a tablet having a hardness of 12 to 20 Kp.
11. In Article 1, The above tablet is a tablet having a friability of 1% or less.
12. (a) A step of preparing a compound comprising a Weilingcai extract, an excipient, and a binder; (b) mixing a pharmaceutically acceptable additive into the above combination; and (c) a step of manufacturing a tablet by compressing the product of step (b) above, Method for manufacturing tablets.
13. In Paragraph 12, A method for preparing a tablet, wherein the above Weilingcai extract is obtained by reflux extracting the whole Weilingcai plant using 40% ethanol, concentrating, drying, and grinding the extract to form a powder.
14. In Paragraph 13, A method for manufacturing a tablet, wherein the above reflux extraction is performed at 100 degrees for 2 hours.
15. In Paragraph 12, A method for manufacturing a tablet, wherein the step of manufacturing the above compound is performed by a wet granulation method.
16. In Paragraph 12, A method for manufacturing a tablet, wherein the above additive is one or more selected from the group consisting of disintegrants and lubricants.
17. In Paragraph 12, A method for manufacturing a tablet, wherein the excipient is a mixture of lactose and microcrystalline cellulose mixed in a weight ratio of 1:1, and is included in an amount of 59 to 72 weight% based on the total weight of the tablet.
18. In Paragraph 12, A method for manufacturing a tablet, wherein the binder is hydroxypropyl cellulose (HPC) and is included in an amount of 3 to 10 weight percent based on the total weight of the tablet.
19. In Paragraph 16, A method for manufacturing a tablet, wherein the disintegrant is crospovidone and is included in an amount of 2 to 10 weight percent based on the total weight of the tablet.
20. In Paragraph 16, A method for manufacturing a tablet, wherein the above-mentioned lubricant is sodium stearyl fumarate and is included in an amount of 1% by weight based on the total weight of the tablet.

Description

Tablet comprising extract of potentilla chinensis and method of producing the same The present invention relates to a tablet containing a Weilingcai extract and a method for manufacturing the same. The human body requires oxygen to sustain life, but oxygen is excessively consumed during cellular metabolic processes due to various factors such as polluted air, alcohol consumption, smoking, and stress. Approximately 90–95% of the total oxygen consumed within the body is used by mitochondria to generate ATP (adenosine triphosphate), while some oxygen (about 1–2%) is converted into ROS (reactive oxygen species), which can then be converted into RNS (reactive nitrogen species) through a chain reaction. If the amount of ROS generated exceeds the amount removed, leading to an excessive accumulation in the body, its high reactivity causes it to readily react with normal cells. Consequently, it binds to major components within the cell, such as proteins, lipids, and nucleic acids, altering their structures and causing cell damage. Representative ROS include oxygen singlet ( 1 O 2 ), superoxide anion radical (O 2 · - ), hydrogen peroxide (H 2 O 2 ), and hydroxyl radical (OH ·), which are known to be major causes of oxidative stress within cells. The human body possesses an antioxidant system designed to prevent oxidative damage caused by ROS and RNS, in which enzymes such as superoxide dismutase, catalase, and peroxidase, as well as antioxidant substances like vitamin C, vitamin E, and glutathione, play key roles. However, this antioxidant system has limitations in completely eliminating excessive reactive oxygen species generated by external stimuli. Consequently, synthetic antioxidants are used to further remove and inhibit reactive oxygen species; however, due to concerns regarding toxicity, interest in safer natural antioxidants has increased, and the exploration and development of antioxidant bioactive compounds derived from various animal and plant materials, such as natural plant extracts, is attracting attention as an important research field. Meanwhile, Potentilla chinensis is a perennial plant belonging to the Rosaceae family, also known as Potentilla scabiosa. It is characterized by growing well in sunny areas and producing yellow flowers. This plant is known to have efficacy in relieving muscle pain, stopping bleeding, detoxifying, and reducing fever. In particular, the whole plant and roots contain large amounts of flavonoid and polyphenol compounds. These compounds exhibit various physiological activities such as anti-inflammatory, antibacterial, capillary strengthening, hemostasis, and analgesic effects, and are reported to be effective in the prevention and treatment of various diseases. Therefore, in this invention, physiologically active compounds derived from Potentilla chinensis were identified, an indicator component was selected, and an analytical procedure validation was established. The aim is to provide a natural antioxidant containing this indicator component as a main ingredient. The following drawings attached to this specification illustrate preferred embodiments of the present invention and serve to further enhance understanding of the technical concept of the present invention together with the detailed description of the invention provided below; therefore, the present invention should not be interpreted as being limited only to the matters described in such drawings. FIG. 1 illustrates the LC-MS/MS analysis results of a Weilingcai extract according to one embodiment of the present invention, where FIG. 1 (a) shows the negative mode MS/MS spectrum of component 1, FIG. 1 (b) shows the negative mode MS/MS spectrum of component 2, and FIG. 1 (c) shows the negative mode MS/MS spectrum of component 3. FIG. 2 illustrates the HPLC-DAD chromatogram and UV spectrum analysis results of a Weilingcai extract according to one embodiment of the present invention, FIG. 2(a) illustrates the HPLC-DAD chromatogram of indicator components 1 to 3 in the Weilingcai extract according to one embodiment of the present invention, FIG. 2(b) illustrates the HPLC-DAD chromatogram of standard Ellagic acid, FIG. 2(c) illustrates the HPLC-DAD chromatogram of standard Isoquercitrin, FIG. 2(d) illustrates the HPLC-DAD chromatogram of standard Miquelianin, and FIG. 2(e) shows the UV spectrum and maximum absorption wavelength of indicator components 1 to 3 in the Weilingcai extract according to one embodiment of the present invention. Figure 3 illustrates the results of a comparative analysis of HPLC-DAD chromatograms of a Weilingcai extract according to one embodiment of the present invention, Figure 3(a) illustrates the HPLC chromatogram and UV spectrum of a Weilingcai extract according to one embodiment of the present invention, and Figure 3(b) illustrates the HPLC chromatogram and UV spectrum of a Miquelianin standard solution. Hereinafter, embodiments of the present invention are described in detail so that those s